OncoCyte Announces Sponsored Symposium at the 2016 American College of Chest Physician’s CHEST 2016 Annual Meeting
October 24 2016 - 6:00AM
OncoCyte Corporation (NYSE MKT:OCX), a developer of novel,
non-invasive blood-based tests for the detection of cancer, today
announced that it will be sponsoring a symposium at the American
College of Chest Physician’s 2016 CHEST Annual Meeting, being held
in Los Angeles from October 22-26. The symposium is titled
Lung Cancer Diagnosis-Challenges and Solutions and
is scheduled for Monday, October 24th and will begin at 10:15am PT
in the Exhibit Hall (Learning Theater 3).
The symposium will feature a group of clinical
experts who will share their perspective on the current challenges
in the management of patients with pulmonary nodules, especially
those determined to be at intermediate risk for lung cancer.
The speakers will use an interactive case-based approach featuring
specific patient profiles to highlight important challenges in the
use of existing technologies to establish a definitive diagnosis.
The panelists will then discuss the need for new biomarkers, their
application, and the level of evidence needed to move these new
diagnostic modalities into clinical practice.
The panel speakers are:
- Anil Vachani, MD, MS - Associate Professor of Medicine at the
Hospital of the University of Pennsylvania and the Veteran’s
Administration Medical Center
- Peter Mazzone, MD, MPH - Director of the Lung Cancer Program
for the Respiratory Institute at Cleveland Clinic, Director of the
Lung Cancer Screening Program
- Nichole T. Tanner, MD, MSCR - Associate Professor of Medicine,
Co-Director, Lung Cancer Screening Program, Division of Pulmonary,
Critical Care, Allergy and Sleep Medicine, Medical University of
South Carolina
Previously, the Company and The Wistar Institute
announced the summary of the analysis of a 610 patient cohort for
their lung cancer diagnostic study which will be presented at
CHEST. The study demonstrates the ability of a lung cancer
test to distinguish malignant from benign lung growths based on
previously identified gene expression signatures, co-developed by
Wistar and OncoCyte, under a license from Wistar. The data
will be presented by lead investigator Louise Showe, Ph.D., on
Tuesday, October 25th at 9:00 am. Dr. Showe is a professor in
the Molecular and Cellular Oncogenesis Program and associate
director for the Center for Systems and Computational Biology at
The Wistar Institute.
About OncoCyte
CorporationOncoCyte is primarily focused on the
development and commercialization of novel, non-invasive blood and
urine (“liquid biopsy”) diagnostic tests for the early detection of
cancer to improve health outcomes through earlier diagnoses, to
reduce the cost of care through the avoidance of more costly
diagnostic procedures, including invasive biopsy and cystoscopic
procedures, and to improve the quality of life for cancer patients.
While current biopsy tests use invasive surgical procedures to
provide tissue samples in order to determine if a tumor is benign
or malignant, OncoCyte is developing a next generation of
diagnostic tests that will be based on liquid biopsies using blood
or urine samples. OncoCyte’s pipeline products are intended to be
confirmatory diagnostics for detecting lung, bladder and breast
cancer. OncoCyte’s diagnostic tests are being developed using
proprietary sets of genetic and protein markers that differentially
express in specific types of cancer.
Forward Looking StatementsAny
statements that are not historical fact (including, but not limited
to statements that contain words such as “will,” “believes,”
“plans,” “anticipates,” “expects,” “estimates” and similar
expressions) should also be considered to be forward-looking
statements. These statements include those pertaining to the
implementation and results of our validation study and other
studies, commercialization plans, future financial and/or operating
results, future growth in research, technology, clinical
development, and potential opportunities for OncoCyte, along with
other statements about the future expectations, beliefs, goals,
plans, or prospects expressed by management. Forward-looking
statements involve risks and uncertainties, including, without
limitation, risks inherent in the development and/or
commercialization of potential diagnostic tests or products,
uncertainty in the results of clinical trials or regulatory
approvals, the need and ability to obtain future capital, and
maintenance of intellectual property rights, and the need to obtain
third party reimbursement for patient’s use of any diagnostic tests
we commercialize. Actual results may differ materially from the
results anticipated in these forward-looking statements and as such
should be evaluated together with the many uncertainties that
affect the business of OncoCyte, particularly those mentioned in
the “Risk Factors” and other cautionary statements found in
OncoCyte’s Securities and Exchange Commission filings. OncoCyte
disclaims any intent or obligation to update these forward-looking
statements, except as required by law.
Investor Contact:
EVC Group, Inc.
Michael Polyviou
646-445-4800
mpolyviou@evcgroup.com